SCHEMBL4161973

SCHEMBL4161973

CNC(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
KDM4E B2RXH2 1/20 0.61
NPC1 O15118 1/20 0.61
MAPT P10636 1/20 0.61
PKM P14618 1/20 0.61
RAB9A P51151 1/20 0.61
HPGD P15428 4/20 0.59
POLB P06746 1/20 0.58
HTT P42858 1/20 0.58
TSHR P16473 1/20 0.57
BCAT2 O15382 1/20 0.54
SLC6A2 P23975 2/20 0.52
SLC6A4 P31645 2/20 0.52
SLC6A3 Q01959 2/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
MAOA P21397 1/20 0.51
MAOB P27338 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27330466 0.84 MEN1 (0.58) MEN1KMT2AKDM4ENPC1MAPT
SCHEMBL2662442 0.84 HSP90AA1 (0.53) MEN1KMT2AKDM4ENPC1MAPT
SCHEMBL3786490 0.84 SMN1; SMN2 (0.55) MEN1KMT2AKDM4ENPC1MAPT
SCHEMBL11959873 0.84 TAS1R3 (0.59) MEN1KMT2AKDM4ENPC1MAPT
SCHEMBL8918916 0.84 NPC1 (0.54) MEN1KMT2AKDM4ENPC1MAPT
SCHEMBL3783986 0.84 PYGL (0.57) MEN1KMT2AKDM4ENPC1MAPT
SCHEMBL4176796 0.82 HDAC8 (0.52) MEN1KMT2AKDM4ENPC1MAPT
SCHEMBL22059501 0.82 HDAC8 (0.47) MEN1KMT2AKDM4ENPC1MAPT
SCHEMBL879253 0.82 ALDH1A1 (0.53) MEN1KMT2AKDM4ENPC1MAPT
SCHEMBL8312487 0.82 KCNQ3 (0.56) MEN1KMT2AKDM4ENPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020182990-A1 FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES Janssen Sciences Ireland Unlimited Company (IE) 2020-09-17 WO disclosed
CN-108752155-A A method of synthesis N- aryl methanamide compounds 西京学院 2018-11-06 CN disclosed
US-8569267-B2 Tetracyclic tetrahydrofuran derivatives containing cyclic amine side chain JANSSEN PHARMACEUTICA, NV (BE) 2013-10-29 US disclosed
US-20130131134-A1 PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF MORITA KOHEI (JP) 2013-05-23 US disclosed
US-20120238750-A1 AROMATIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2012-09-20 US disclosed
US-8188277-B2 Aromatic compounds for suppressing the generation of collagen OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-05-29 US disclosed
US-20100234378-A1 ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-09-16 US disclosed
US-20090131657-A1 PROCESS FOR ALKENYLATING CARBOXAMIDES BASF SE (DE) 2009-05-21 US disclosed
US-20080262076-A1 Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain JANSSEN PHARMACEUTICA, NV (BE) 2008-10-23 US disclosed
US-20080262076-A1 Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain JANSSEN PHARMACEUTICA, NV (BE) 2008-10-23 US disclosed
US-7432264-B2 Antimicrobial biaryl compounds ISIS PHARMACEUTICALS, INC. (US) 2008-10-07 US disclosed
US-7432264-B2 Antimicrobial biaryl compounds ISIS PHARMACEUTICALS, INC. (US) 2008-10-07 US disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 US disclosed
WO-2007066784-A2 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 WO disclosed
US-3959269-A TRANQUILIZERS, SEDATIVES SANDOZ, INC. (US) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234378-A1 ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS MMP3, MMP11, MMP13 MEN1 2931/4885KMT2A 1293/4885KDM4E 1033/4885
US-20080262076-A1 Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain HTR2C, HTR2A, HTR5A MEN1 4320/4885KMT2A 1892/4885KDM4E 4597/4885
US-20120238750-A1 AROMATIC COMPOUND CBR1, CBR3, CYP1A1 MEN1 1020/4885KMT2A 984/4885KDM4E 1219/4885
US-20130131134-A1 PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF PLA2G12A, PLA2G4A, PLA2G4B MEN1 4753/4885KMT2A 1631/4885KDM4E 1591/4885
US-20070270422-A1 Aromatic Compounds COL1A1, COL2A1, COL14A1 MEN1 3512/4885KMT2A 2349/4885KDM4E 988/4885
US-20090131657-A1 PROCESS FOR ALKENYLATING CARBOXAMIDES PRMT5, CYC1, CBR3 MEN1 303/4885KMT2A 41/4885KDM4E 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.